Take­da, CSL Behring fold big plas­ma al­liance af­ter PhI­II flop — join­ing a slew of an­ti­bod­ies that failed to help hos­pi­tal­ized pa­tients

The big plas­ma al­liance spear­head­ed by Take­da and CSL Behring has a big Phase III ver­dict: Adding their hy­per­im­mune in­tra­venous im­munoglob­u­lin prod­uct to Gilead’s remde­sivir does not stall dis­ease pro­gres­sion.

Dubbed H-Ig, the treat­ment was sup­posed to be a high­er grade ver­sion of con­va­les­cent plas­ma, which for­mer Pres­i­dent Don­ald Trump once hailed as a “his­toric break­through.” But it seems to be fol­low­ing plas­ma down the same path to­ward ob­so­les­cence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER